SEC Form 4 · accession 0001209191-19-010144
Deciphera Pharmaceuticals, Inc. · DCPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Arthur Bristol
Director
Period of report
Feb 12, 2019
Accepted (ET)
Feb 14, 2019 · 4:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001654151
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 12, 2019 | M | 600 | $1.89 | A | 600 | D | |
| Common StockF2 | Feb 12, 2019 | S | 600 | $28.0017 | D | 0 | D | |
| Common Stock | Feb 13, 2019 | M | 2,922 | $1.89 | A | 2,922 | D | |
| Common StockF3 | Feb 13, 2019 | S | 2,922 | $28.0067 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $1.89 | Feb 12, 2019 | M | 600 | D | — | Dec 17, 2025 | Common Stock | 600 | 135,213 | D |
| Stock Option (Right to Buy)F4 | $1.89 | Feb 13, 2019 | M | 2,922 | D | — | Dec 17, 2025 | Common Stock | 2,922 | 132,291 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.01, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.07, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F4This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015.